Key result
Catheter-based renal sympathetic denervation significantly reduced office blood pressure by a mean of -32/-12 mm Hg at 6 months compared to 1/0 mm Hg in the control group among patients with resistant hypertension.
Why the study?
Does catheter-based renal denervation reduce blood pressure in patients with resistant hypertension?
Does catheter-based renal denervation reduce blood pressure in patients with resistant hypertension?
Absolute Event Rate: -32% vs 1%
Catheter-based renal denervation is a promising, minimally invasive procedure that significantly lowers blood pressure in patients with resistant hypertension, though further study is needed to confirm long-term efficacy and safety.
Supports renal denervation for resistant hypertension; leaves open long-term safety and optimal selection.
Renal sympathetic denervation has shown promise in treating hypertension resistant to drug therapy. This procedure lowers blood pressure via targeted attenuation of renal sympathetic tone, and it has a favorable safety profile. But although there is reason for cautious optimism, we should keep in mind that the mechanisms of hypertension are complex and multifactorial, and further study of this novel therapy and its long-term effects is needed.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2012) conducted a review in Resistant hypertension. Renal sympathetic denervation vs. Antihypertensive medications alone was evaluated on Change in seated office systolic blood pressure from baseline to 6 months (Symplicity HTN-2). Catheter-based renal sympathetic denervation significantly reduced office blood pressure by a mean of -32/-12 mm Hg at 6 months compared to 1/0 mm Hg in the control group among patients with resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: